Hydrogels as delivery platforms for advancing T cell therapies
Abstract
ABSTRACT Gene-modified T cell immunotherapies, particularly Chimeric Antigen Receptor (CAR) T cell therapy, have transformed the landscape of cancer treatment, demonstrating remarkable success in various hematological malignancies. However, their application in solid tumors remains significantly limited, primarily due to poor T cell trafficking and tumor infiltration - caused by physical barriers, hypoxia and the immunosuppressive tumor microenvironment. To address these challenges, hydrogels have emerged as promising delivery platforms for CAR T cells, aiming to improve both therapeutic efficacy and safety. In this review, we highlight recent advances in this field, with a focus on hydrogel-based strategies for enhancing CAR T cell therapy in non-hematologic malignancies.
Fields of Study & Subjects
CAR-T cell therapy research
Monoclonal and Polyclonal Antibodies Research
Immunotherapy and Immune Responses
Publication details
- Journal / source
- Journal of Drug Delivery Science and Technology
- Publisher
- Elsevier BV
- Volume
- 119
- Pages
- 108195–108195
- Publication date
- 28 February 2026
- Language
- EN